Genentech vet sets up deal-making shop

20-year Genentech veteran Suzy Jones has left the biotech giant to set up her own shop helping small biotechs negotiate drug deals with the big boys in the biopharma industry. Jones says that DNA Ink already has two clients on board and is close to signing deals with more. There's so much good science out there and there are buyers," Jones told the San Francisco Business Times. "We'll do great deals and we'll do them quickly." Story

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.